REAL-WORLD TREATMENT PATTERNS AND OUTCOMES WHEN INITIATING ONCE-DAILY INJECTABLE PEN THERAPY WITH INSULIN GLARGINE OR LIRAGLUTIDE - AN ELECTRONIC MEDICAL RECORDS STUDY

被引：0
|
作者：
Mersey, J. [1 ]
Wei, W. [2 ]
Meyers, J. [3 ]
Wang, C. C. [3 ]
Dalal, M. R. [2 ]
Bromberger, L. A. [1 ]
Levin, P. [4 ]
机构：
[1] MODEL Clin Res, Baltimore, MD USA
[2] Sanofi Aventis US, Bridgewater, NJ USA
[3] RTI Hlth Solut, Res Triangle Pk, NC USA
[4] Bay W Endocrinol Associates, Baltimore, MD USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1648
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A494 / A494
页数：1
相关论文
共 50 条
  • [41] The real-world observational prospective study of health outcomes with dula and liraglutide in type 2 diabetes patients (TROPHIES): 24-m clinical characteristics and treatment patterns
    Dib, A.
    Guerci, B.
    Giorgino, F.
    Boye, K.
    Fuchtenbusch, M.
    Heitmann, E.
    Lebrec, J.
    Federici, M. Orsini
    Yu, M.
    Garcia-Perez, L. -E.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S315 - S316
  • [42] Treatment Patterns and Outcomes Among Patients with Higher-Risk Myelodysplastic Syndromes Treated in a Real-World Setting: Electronic Medical Record-Based Data
    Bell, Jill A.
    Galaznik, Aaron
    Farrelly, Eileen
    Blazer, Marlo
    Seal, Brian
    Shih, Huai-Che
    Ogbonnaya, Augustina
    Eaddy, Michael
    Dezube, Bruce J.
    BLOOD, 2016, 128 (22)
  • [43] DOES DEVICE MATTER AND AT WHAT COST? REAL-WORLD COMPARATIVE STUDY OF INSULIN GLARGINE TREATMENT USING DISPOSABLE PEN VERSUS VIAL/SYRINGE IN MEDICAID PATIENTS WITH TYPE-2 DIABETES MELLITUS
    Cao, Z.
    Thomson, E.
    Ling, Z.
    Miao, R.
    Wei, W.
    VALUE IN HEALTH, 2013, 16 (03) : A156 - A156
  • [44] Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database
    Chari, Ajai
    Ung, Brian
    Abouzaid, Safiya
    Ni, Quanhong
    Parikh, Kejal
    Agarwal, Amit
    BLOOD, 2017, 130
  • [45] Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naive cohort study
    Bailey, Timothy S.
    Zhou, Fang L.
    Gupta, Rishab A.
    Preblick, Ronald
    Gupta, Vineet E.
    Berhanu, Paulos
    Blonde, Lawrence
    DIABETES OBESITY & METABOLISM, 2019, 21 (07): : 1596 - 1605
  • [46] Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy:: The SWITCH pilot study
    Schiel, R.
    Mueller, U. A.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2008, 116 (01) : 58 - 64
  • [47] Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy:: The switch pilot study
    Schiel, R.
    Mueller, Ulrich A.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2007, 115 (10) : 627 - 633
  • [48] Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study (vol 21, 1207, 2021)
    Atrash, Shebli
    Thompson-Leduc, Philippe
    Tai, Ming-Hui
    Kaila, Shuchita
    Gray, Kathleen
    Ghelerter, Isabelle
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Rossi, Adriana
    BMC CANCER, 2021, 21 (01)
  • [49] Treatment patterns, effectiveness, and patient-reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real-world study
    Shen, Lesang
    Zhou, Jun
    Chen, Yiding
    Ding, Jinhua
    Wei, Haiyan
    Liu, Jian
    Xia, Wenjie
    Xie, Bojian
    Xie, Xiaohong
    Li, Xujun
    Dai, Yuechu
    Zhang, Guobing
    Qiu, Xia
    Li, Chao
    Sun, Shanshan
    Chen, Wuzhen
    Gong, Dihe
    Li, Hengyu
    Huang, Jian
    Jiang, Xia
    Ni, Chao
    CANCER MEDICINE, 2022, 11 (22): : 4157 - 4168
  • [50] Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry
    Dimitrios A. Pappas
    Jacqueline O’Brien
    Lin Guo
    Ying Shan
    Joshua F. Baker
    Gregory Kricorian
    Scott Stryker
    David H. Collier
    Arthritis Research & Therapy, 25
12345